BridgeBio Pharma, Inc.
BBIO
NASDAQ·Healthcare·Biotechnology·Mkt cap $14.7B
$74.84
▼ -0.76%
P/E
-20.91
Mkt Cap
$14.7B
52-Wk Range
$48.78–$93.42
52-Week Range
$48.78 - $93.42
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 37.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Diversified pipeline of 30 programs reduces development risk and provides multiple revenue opportunities
- Strategic academic partnerships with Stanford and UC Berkeley provide access to cutting-edge research and early-stage assets
- Focus on genetically-defined rare diseases with high unmet medical needs and potential for premium pricing
- Experienced management team with deep expertise in genetic disease biology and drug development
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Strong revenue growth (126% YoY)
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Strong
+11.1% over 3m
Quality
Excellent
High-growth business (188% revenue growth, 93% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying BBIO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 28, 2026
AUG 10, 2026
Reported EPS of -$0.78 vs -$0.58 consensus (-35.5% surprise). Revenue of $243.7M vs $220.9M expected (+10.3%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-35.5%
Revenue trend · last 8Q
—
+237%
-45%
—
+4318%
+2521%
+67%
+89%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.7M
$5.9M
$116.6M
$110.6M
$120.7M
$154.2M
$194.5M
$208.5M
Margins · last 8Q
Gross
—
Operating
-51.4%
Profit
-73.0%
Wall Street consensus
11 analysts · 82% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
82%
Hold
18%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 12, 2026
vs Industry
How BBIO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related